Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2011 Jul;70(7):596–609. doi: 10.1097/NEN.0b013e31822146ca

Figure 3.

Figure 3

Immunohistochemical expression profiles of CDK4 and cyclinD1 in atypical teratoid/rhabdoid (AT/RT) and non-CNS malignant rhabdoid tumors (MRT). (A) CDK4 immunostaining showed weak (1+) expression in AT/RT. (B) Semiquantitative estimation of CDK4 shows weak expression in both AT/RT and non-CNS MRT. (C) Focal weak (1+) expression of cyclin D1 staining in AT/RT. (D) Semiquantitative estimation of cyclinD1 showed focal weak expression in both AT/RT and non-CNS MRT. The y-axes in B and D represent a semiquantitative measure of the product of staining intensity and percentage of positive cells in each case.